Volume 96 Issue 9 | pp. 14-15 | Concentrates
Issue Date: February 26, 2018

Merck will acquire oncolytic virus firm

By Ryan Cross
Department: Business
Keywords: Oncology, Merck, oncolytic viruses

Merck & Co. will pay about $400 million to acquire the Australian biotech firm Viralytics, which is testing an oncolytic virus, part of a small but growing class of cancer therapies. The virus, which infects and kills cancer cells, will be used alongside Merck’s immunotherapy Keytruda in an attempt to expand the number of cancers and people for which Keytruda is effective.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment